Clinical trial
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial…
NCT00163501 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00163501 |
|---|---|
| Title | Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever |
| Intervention type | Drug |
| Interventions | Ciclesonide |
| Enrollment | 600 |
| Start date | Dec 1, 2003 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 30, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: